CClinicalTrials.gg
CompletedNCT03645941CAN QuitUpdated Jun 8, 2022Results posted

Connecting Alaska Native People to Quit Smoking

An interventional study of Facebook Group in Tobacco Use, Tobacco Smoking and Tobacco Use Cessation, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-08.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The prevalence of smoking among US adults is highest among American Indians and Alaska Native (AI/AN) persons; however, there are a lack of tobacco cessation interventions developed specific to this disparity group. Social media holds promise as a scalable intervention strategy to promote engagement in treatment and cessation outcomes for Alaska Native (AN) people.

Researchers plan to develop and pilot test a culturally relevant, Facebook delivered intervention to promote smoking treatment uptake and cessation among AN smokers. The Facebook content will include a digital storytelling approach adapted from the effective Centers for Disease Control (CDC) Tips from Former Smokers educational mass media campaign. The project builds on the researcher team's longstanding tobacco control research partnership with the AN community and was informed by their understanding of cultural factors that can both impede and encourage cessation in this population. If the pilot intervention is successful, researchers will have a blueprint to conduct a large randomized controlled trial. The researchers long-term objective is to develop interventions for AN tobacco users that will ultimately reduce their risk of tobacco-caused disease and mortality.

Read the detailed description

The Behavioral Health Research Program at Mayo Clinic will be coordinating the study (recruit, train, oversee, etc.), but the project will take place in Alaska. The study will be conducted at the Alaska Native Tribal Health Consortium (ANTHC) in Anchorage. All data collection and the intervention will be conducted by study staff at ANTHC and Mayo Clinic. For qualitative data collection, a semi-structured interviewer guide will be developed and the project coordinator in Alaska will conduct the interviews. Researchers will provide training for the project coordinator on-site in Anchorage including 4 hours of didactic instruction followed by 4 practice hours of mock interviews and a certified completion interview. All sessions will be audiotaped. These transcripts will be coded by the researchers to assess counselor adherence to the proscribed intervention, and feedback will be provided during weekly research team teleconferences.

Mayo Clinic social media department will create the Facebook group page, develop the content library of moderator postings, and set up the software to capture participant use data. A random sample of 20% of moderator postings and responses to participant inquiries and discussions will be selected every week for the first four weeks and monthly thereafter. These transcripts will be coded by the researchers to assess moderator adherence to the proscribed intervention, and feedback will be provided during weekly research team teleconferences.

A manual of study procedures will be developed for the project coordinator in Alaska (AK). A Mayo Clinic program coordinator and clinical trials coordinator, will travel with a Mayo Clinic Co-Investigator to Anchorage, AK, to train the project coordinator on the data collection and other study procedures. The same coordination, communication, and quality control procedures will be used that have been successfully utilized in previous work. For ongoing trials in Alaska, weekly conference calls are scheduled with study staff in AK and at Mayo Clinic to discuss progress and problem solve issues related to recruitment and data collection. Quality control of the data is also monitored on site through review of participant forms and procedures every 3 months. The biostatistician on this protocol will oversee the transfer of data forms, electronic data, and data storage. The Mayo Survey Research Center will electronically transfer all data to the biostatistician. The quality of the data (data checks) including missing data and presence and frequency of outliers will be monitored once per month by the biostatistician. For study recruitment, the project coordinator will track posting of ads through Facebook (FB) and in Alaska local newsletters and websites.

All measures will be administered online using Qualtrics software, a data security service. An email link will be sent automatically by the Mayo Clinic Survey Research Center to complete the assessment. If a participant does not complete online assessments, the participant will be contacted through email or by phone by the project coordinator and prompted to complete the assessment. Data collected from survey responses will be handled and maintained by the Mayo Clinic Survey Research Center and a de-identified database of responses will be provided to the investigators. Interview forms and audio tapes will be labeled with subject ID numbers only; all personal identifiers will be removed before the data are sent to Mayo Clinic for analysis. At Mayo Clinic the audio tapes will be stored in a locked file drawer accessible only to the PI, Co-Investigator, and the project coordinator. These will be destroyed once the interviews are fully transcribed.

A trained research assistant at Mayo Clinic will mail the saliva sample kit to the participant; and the saliva samples, labeled with a subject identifier (ID) number only, will be shipped directly back to Mayo Clinic for analysis of cotinine. Once the specimen sample is processed and results posted, the sample will be destroyed immediately.

The study staff in Anchorage and Rochester will monitor any reports or observations of medical problems or severe depression or other psychiatric symptoms in participants. The Principal Investigator (PI) and a Co-Investigator from Stanford University, licensed clinical psychologists, will be consulted by telephone to consult with the study staff as needed.

02

Conditions studied

  • Tobacco Use
  • Tobacco Smoking
  • Tobacco Use Cessation
  • Smoking Cessation
  • Smoking, Cigarette
  • Smoking, Tobacco
  • Smoking

Keywords

  • Social Media
  • Alaska Native
03

In context

Lead sponsor

Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.

Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion and Exclusion Criteria

Participants must be:

  1. >19 years of age (legal smoking age),
  2. Alaska Native race/ethnicity,
  3. smoke at least 1 cigarette per day over the past 7 day period,
  4. if other tobacco use, cigarettes are the main tobacco product used,
  5. considering or willing to make a quit attempt,
  6. access to internet,
  7. have an existing Facebook account or willing to set up an account, and
  8. is not using pharmacotherapy or has not enrolled in a program to stop smoking for past 3 months.

    • Each person is only eligible to participate in one part of the study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • No intervention
    Quitline/Treatment Referral

    Description of tobacco treatment services, phone numbers and web links sent via postal mail (printed materials) and email. Treatment options provide free, professional assistance based on U.S. clinical practice guidelines: (1)AK quitline, (2)regional tribal tobacco cessation programs, and (3)smokefree.gov resources (e.g., free texting program and smartphone application, quit guide)

  • Experimental
    Facebook+Quitline/Treatment Referral

    * Participants join a secret/private, culturally relevant Facebook group moderated by an AN tobacco research counselor for 3 months * Once daily moderator postings for 30 days, repeated each month for 3 months; plus 3-4 daily check-ins/postings to respond to participant generated content and encourage sharing of personal stories/experiences relevant to all stages of the quitting process and treatment engagement * Description of tobacco treatment services, phone numbers and web links sent via postal mail (printed materials) and email. Treatment options provide free, professional assistance based on U.S. clinical practice guidelines: (1)AK quitline, (2)regional tribal tobacco cessation programs, and (3)smokefree.gov resources (e.g., free texting program and smartphone application, quit guide)

    Behavioral: Facebook Group

Interventions

  • BehavioralFacebook Group

    The pilot trial, a two-arm, parallel groups, randomized controlled design, will enroll 60 participants randomized with 1:1 allocation to the intervention or control condition. Participants will be randomized within stratified blocks based on sex (male, female), age group (19-29, 30-49, 50+ years), and region (urban, rural); potential variables related to outcomes. Assessments will be conducted for both study groups at baseline and at 1, 3, and 6 month follow-up.

06

What researchers measure

Primary outcomes

  1. Smoking Cessation Program Completion

    The number of participants that completed the smoking cessation program and all activities per protocol

    Time frame: 6 month follow-up assessment

  2. Biochemically Confirmed Abstinence From Smoking

    Number of participants to have biochemically verified smoking abstinence by saliva specimen with cotinine level \<15ng/ml

    Time frame: 6 months

Secondary outcomes

  1. Self-reported 7-day Point Prevalence Smoking Abstinence

    Number of participants to self-report smoking abstinence during the past seven days (not even a puff)

    Time frame: 6 months

  2. Self-reported Use of Evidence-based Cessation Treatments

    Number of participants to self-report use of evidence-based cessation treatments including Alaska's Tobacco Quitline, Tribal cessation programs, cessation assistance from a health care provider, nicotine replacement therapy, and other stop-smoking medications.

    Time frame: 6 months

  3. Quit Attempts

    Number of participants to self-report a quit attempts since enrollment

    Time frame: 6 months

07

Results

Posted Jun 8, 2022

Participant flow

Participant flow — Overall Study
MilestoneQuitline/Treatment ReferralFacebook+Quitline/Treatment Referral
Started3031
Completed1619
Not completed1412

Outcome measures

PrimarySmoking Cessation Program Completion

The number of participants that completed the smoking cessation program and all activities per protocol

Time frame:
6 month follow-up assessment
Reported as:
Count of participants · Participants
Smoking Cessation Program Completion
ParticipantsQuitline/Treatment ReferralFacebook+Quitline/Treatment Referral
Smoking Cessation Program Completion1619
PrimaryBiochemically Confirmed Abstinence From Smoking

Number of participants to have biochemically verified smoking abstinence by saliva specimen with cotinine level \<15ng/ml

Time frame:
6 months
Reported as:
Count of participants · Participants
Biochemically Confirmed Abstinence From Smoking
ParticipantsQuitline/Treatment ReferralFacebook+Quitline/Treatment Referral
Biochemically Confirmed Abstinence From Smoking22
SecondarySelf-reported 7-day Point Prevalence Smoking Abstinence

Number of participants to self-report smoking abstinence during the past seven days (not even a puff)

Time frame:
6 months
Reported as:
Count of participants · Participants
Self-reported 7-day Point Prevalence Smoking Abstinence
ParticipantsQuitline/Treatment ReferralFacebook+Quitline/Treatment Referral
Self-reported 7-day Point Prevalence Smoking Abstinence73
SecondarySelf-reported Use of Evidence-based Cessation Treatments

Number of participants to self-report use of evidence-based cessation treatments including Alaska's Tobacco Quitline, Tribal cessation programs, cessation assistance from a health care provider, nicotine replacement therapy, and other stop-smoking medications.

Time frame:
6 months
Reported as:
Count of participants · Participants
Self-reported Use of Evidence-based Cessation Treatments
ParticipantsQuitline/Treatment ReferralFacebook+Quitline/Treatment Referral
Self-reported Use of Evidence-based Cessation Treatments48
SecondaryQuit Attempts

Number of participants to self-report a quit attempts since enrollment

Time frame:
6 months
Reported as:
Count of participants · Participants
Quit Attempts
ParticipantsQuitline/Treatment ReferralFacebook+Quitline/Treatment Referral
Quit Attempts1113

Adverse events

Collected over Adverse events were collected from baseline to end of study participation for a total of approximately 6 months on all participants. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Quitline/Treatment Referral0/30 (0%)0/30 (0%)0/30 (0%)
Facebook+Quitline/Treatment Referral0/31 (0%)0/31 (0%)0/31 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Quitline/Treatment ReferralFacebook+Quitline/Treatment ReferralTotal
Mean39.5 ± 11.041.2 ± 12.940.3 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Quitline/Treatment ReferralFacebook+Quitline/Treatment ReferralTotal
Female191938
Male111223
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Quitline/Treatment ReferralFacebook+Quitline/Treatment ReferralTotal
American Indian or Alaska Native303161
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Quitline/Treatment ReferralFacebook+Quitline/Treatment ReferralTotal
United States303161
08

Study locations

1 site
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
09

References and documents

Publications

  • Merculieff ZT, Koller KR, Sinicrope PS, Hughes CA, Bock MJ, Decker PA, Resnicow K, Flanagan CA, Meade CD, McConnell CR, Prochaska JJ, Thomas TK, Patten CA. Developing a Social Media Intervention to Connect Alaska Native People Who Smoke with Resources and Support to Quit Smoking: The Connecting Alaska Native Quit Study. Nicotine Tob Res. 2021 May 24;23(6):1002-1009. doi: 10.1093/ntr/ntaa253. PubMed 33674856 ↗

Study documents

  • Protocol and statistical analysis plan · Sep 30, 2021
  • Informed consent form · Mar 24, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — All data elements and data transfer activities will be strictly compliant with HIPAA privacy regulatory requirements.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03645941
Lead sponsor
Mayo Clinic
Collaborators
National Institute on Drug Abuse (NIDA)
Responsible party
Christi Patten (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Aug 24, 2018
Start date
Dec 13, 2019
Primary completion
Mar 26, 2021
Completion
Mar 26, 2021
Results posted
Jun 8, 2022
Last update
Jun 8, 2022

Study contacts

Christi A Patten, Ph.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion